RPG Life Sciences Reports Mixed Financial Results Amidst Sales Decline in March 2025
RPG Life Sciences has reported its financial results for the quarter ending March 2025, showing a year-on-year growth in Profit After Tax of 42.76% at Rs 56.68 crore. However, challenges include a decline in Profit Before Tax and a decrease in net sales, indicating mixed performance overall.
RPG Life Sciences has recently reported its financial results for the quarter ending March 2025, revealing a complex picture of performance within the pharmaceuticals and drugs industry. The company has experienced a notable adjustment in its evaluation, with its score reflecting a shift from 10 to -1 over the past three months.On a positive note, the Profit After Tax (PAT) for the latest six months stands at Rs 56.68 crore, showcasing a year-on-year growth of 42.76%. This indicates a favorable near-term trend in profitability, contributing to higher earnings for shareholders. Additionally, the Earnings per Share (EPS) reached Rs 70.96, marking the highest level in the last five quarters, which underscores the company's ability to generate increased earnings.
Conversely, the financial results also highlight challenges for RPG Life Sciences. The Profit Before Tax (PBT), excluding other income, has shown a decline, recorded at Rs 19.94 crore, which is significantly lower than the average PBT of Rs 33.44 crore from the previous four quarters. Furthermore, net sales have decreased to Rs 143.09 crore, down 10.2% compared to the previous quarter's average. The non-operating income, while at its highest in five quarters at Rs 5.06 crore, raises questions about its sustainability.
Overall, RPG Life Sciences' recent financial results reflect a mix of positive growth in profitability metrics alongside notable declines in sales and PBT, leading to a revision in its score.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
